Evidence map›Paper›PMID 41029369›Full record

ArticleCardiovascular diabetology2025

Associations of six insulin resistance-related indices with the risk and progression of cardio-renal-metabolic multimorbidity: evidence from the UK biobank.

Lulu Liu, Guangzan Yu, Xuhou Ji, Yunlong Wang, Hua He

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lulu LiuCardiac Division of Emergency Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People's Republic of China.
Guangzan YuCardiac Division of Emergency Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People's Republic of China.
Xuhou JiCardiac Division of Emergency Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People's Republic of China.
Yunlong WangArrhythmia Center, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People's Republic of China.
Hua HeCardiac Division of Emergency Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, People's Republic of China. hehua430@163.com.

Funding

Natural Science Foundation of Beijing Municipality 7202037
6 · The paper itself

Abstract

backgroundInsulin resistance (IR)-related indices are increasingly recognized as important contributors to cardio-renal-metabolic (CRM) diseases. However, most prior studies have focused on isolated outcomes or cross-sectional disease status, lacking dynamic insight into disease progression. This study aimed to evaluate the predictive value of six IR-related indices for CRM onset and multistage progression using multistate modeling, and to explore potential biological mechanisms through mediation analysis.

methodsWe included 327,692 CRM-free participants from the UK Biobank in this prospective cohort study. Six IR-related indices including triglyceride-glucose (TyG) index, TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), TyG-waist-to-height ratio (TyG-WHtR), triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio, and metabolic score for insulin resistance (METS-IR), were calculated using established formulas. Cox proportional hazards and multistate models were used to assess associations with CRM incidence and progression. Predictive performance was evaluated using area under the curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Mediation analysis was conducted for inflammatory, hepatic, and renal biomarkers.

resultsOver a mean follow-up of 13.6 years, 17.3% (n = 58,563) of participants developed at least one CRM disease. All six IR-related indices were significantly associated with CRM multimorbidity, both in terms of incidence and progression. In predicting the incidence of CRM diseases, TyG-WC, TyG-WHtR, and METS-IR demonstrated superior performance. For each 1-standard deviation (SD) increase in TyG-WC, the risks of developing first, double, and triple CRM diseases increased by 51.4%, 88.6%, and 128.7%, respectively (all P < 0.001), with similar gradients observed for TyG-WHtR and METS-IR. Multistate Cox models further confirmed consistent associations between IR-related indices and CRM progression, particularly for TyG-WHtR and TyG. Specifically, a 1-SD increase in TyG-WHtR was associated with a 65.3% increased risk of transitioning from healthy to first CRM disease, 34.6% from first to double, and 26.7% from double to triple CRM diseases (all P < 0.001). In predictive performance evaluation, TyG-WC, TyG-WHtR, and METS-IR achieved the highest AUC, NRI, and IDI values. Mediation analyses indicated that systemic inflammation, organ function, and especially kidney function partially mediated the observed associations.

conclusionIn summary, IR-related indices, particularly TyG-WC, TyG-WHtR, and METS-IR, were observed to be associated with the presence and progression of CRM diseases. Their potential incorporation into risk assessment and prevention strategies, together with consideration of inflammatory and organ function pathways, might help reduce the burden of CRM multimorbidity; however, further prospective studies are needed to confirm these findings and clarify their clinical relevance.

Indexed as

Insulin ResistanceKidney DiseasesMetabolic SyndromeAdultAgedBiological Specimen BanksBiomarkersBlood GlucoseCardiometabolic Risk FactorsComorbidityDisease ProgressionFemaleHumansIncidenceLipidsMaleBiomarkersBlood GlucoseLipidsTriglyceridesCardio-renal-metabolic multimorbidityInsulin resistanceMediationMulti-state modelUK biobank

Identifiers

PMID41029369
PMCPMC12487372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.